Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models

• Main Authors: Emilia Rabia (Author), Véronique Garambois (Author), Julie Hubert (Author), Marine Bruciamacchie (Author), Nelly Pirot (Author), Hélène Delpech (Author), Morgane Broyon (Author), Charles Theillet (Author), Pierre-Emmanuel Colombo (Author), Nadia Vie (Author), Diego Tosi (Author), Celine Gongora (Author), Lakhdar Khellaf (Author), Marta Jarlier (Author), Nina Radosevic-Robin (Author), Thierry Chardès (Author), André Pèlegrin (Author), Christel Larbouret (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Chemoresistance, particularly to gemcitabine, is a major challenge in pancreatic cancer. The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptors 2 and 3 (HER2, HER3) are expressed in many tumors, and they are relevant therapeutic targets due to their synergistic inter...